Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

FIGO 1988 versus 2009 staging for endometrial carcinoma: a comparative study on prediction of survival and stage distribution according to histologic subtype.

Haltia UM, Bützow R, Leminen A, Loukovaara M.

J Gynecol Oncol. 2014 Jan;25(1):30-5. doi: 10.3802/jgo.2014.25.1.30. Epub 2014 Jan 8.

2.

[Significance of prognostic evaluation of International Federation of Gynecology and Obstetrics 2009 staging system on stage I endometrioid adenocarcinoma].

Wang ZQ, Zhang Y, Wang JL, Shen DH, Mu T, Zhao X, Yao YY, Bai Y, Wei LH.

Zhonghua Fu Chan Ke Za Zhi. 2012 Jan;47(1):33-9. Chinese.

PMID:
22455691
3.
4.

Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratification.

Werner HM, Trovik J, Marcickiewicz J, Tingulstad S, Staff AC, Amant F, Salvesen HB; MoMaTEC study group.

Gynecol Oncol. 2012 Apr;125(1):103-8. doi: 10.1016/j.ygyno.2011.11.008. Epub 2011 Nov 17.

PMID:
22100838
6.

Lymphadenectomy increases the prognostic value of the revised 2009 FIGO staging system for endometrial cancer: a multi-center study.

Kim HS, Kim HY, Park CY, Lee JM, Lee JK, Cho CH, Kim SM, Kim JW.

Eur J Surg Oncol. 2012 Mar;38(3):230-7. doi: 10.1016/j.ejso.2011.12.023. Epub 2012 Jan 13.

PMID:
22244682
7.

[Impact of 2009 FIGO staging system on the diagnostic value of preoperative MRI staging of endometrial carcinoma].

Yu XD, Ouyang H, Lin M, Zhou CW, Zhang R.

Zhonghua Zhong Liu Za Zhi. 2011 Sep;33(9):692-6. Chinese.

PMID:
22340052
8.

Redefining stage I endometrial cancer: incorporating histology, a binary grading system, myometrial invasion, and lymph node assessment.

Barlin JN, Soslow RA, Lutz M, Zhou QC, St Clair CM, Leitao MM Jr, Iasonos A, Hensley ML, Barakat RR, Matias-Guiu X, Abu-Rustum NR.

Int J Gynecol Cancer. 2013 Nov;23(9):1620-8. doi: 10.1097/IGC.0b013e3182a5055e.

9.

Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.

Hiura M, Nogawa T, Matsumoto T, Yokoyama T, Shiroyama Y, Wroblewski J.

Int J Gynecol Cancer. 2010 Aug;20(6):1000-5. doi: 10.1111/IGC.0b013e3181d80aff.

PMID:
20683408
10.

Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma.

Bildrici K, Tel N, Ozalp SS, Yalcin OT, Yilmaz V.

Eur J Gynaecol Oncol. 2002;23(6):540-4.

PMID:
12556100
11.

The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.

Cirisano FD Jr, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS, Soper JT, Clarke-Pearson DL.

Gynecol Oncol. 2000 Apr;77(1):55-65.

PMID:
10739691
12.

Peritoneal washing cytology in gynecologic cancers: long-term follow-up of 355 patients.

Zuna RE, Behrens A.

J Natl Cancer Inst. 1996 Jul 17;88(14):980-7.

PMID:
8667429
13.

Prior Tubal Ligation Might Influence Metastatic Spread of Nonendometrioid Endometrial Carcinoma.

Li M, Li M, Zhao L, Wang Z, Wang Y, Shen D, Wang J, Wei L.

Int J Gynecol Cancer. 2016 Jul;26(6):1092-7. doi: 10.1097/IGC.0000000000000727.

14.

Revaluating the survival effects of International Federation of Gynecology and Obstetrics 1988 stage IIIA criteria for endometrial cancer.

Türkmen O, Karalok A, Başaran D, Kimyon G, Kul G, Tulunay G, Üreyen I, Turan T.

J Turk Ger Gynecol Assoc. 2017 Sep 1;18(3):110-115. doi: 10.4274/jtgga.2017.0033.

15.

A comparison of uterine papillary serous, clear cell carcinomas, and grade 3 endometrioid corpus cancers using 2009 FIGO staging system.

Kim HJ, Kim TJ, Lee YY, Choi CH, Lee JW, Bae DS, Kim BG.

J Gynecol Oncol. 2013 Apr;24(2):120-7. doi: 10.3802/jgo.2013.24.2.120. Epub 2013 Apr 5.

16.

Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?

Alektiar KM, McKee A, Lin O, Venkatraman E, Zelefsky MJ, McKee B, Hoskins WJ, Barakat RR.

Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):79-85.

PMID:
12182977
17.

[Predictors of recurrence and prognosis in patients with stage I and II endometrial carcinoma].

Li M, Wang Z, Zhao L, Li X, Wang J, Zhang C, Wei L.

Zhonghua Fu Chan Ke Za Zhi. 2014 Jun;49(6):455-9. Chinese.

PMID:
25169640
18.

The significance of the amount of myometrial invasion in patients with Stage IB endometrial carcinoma.

Alektiar KM, McKee A, Lin O, Venkatraman E, Zelefsky MJ, Mychalczak BR, McKee B, Hoskins WJ, Barakat RR.

Cancer. 2002 Jul 15;95(2):316-21.

19.

Outcomes of patients with uterine serous carcinoma using the revised FIGO staging system.

Seward S, Ali-Fehmi R, Munkarah AR, Semaan A, Al-Wahab ZR, Elshaikh MA, Cote ML, Morris RT, Bandyopadhyay S.

Int J Gynecol Cancer. 2012 Mar;22(3):452-6. doi: 10.1097/IGC.0b013e31823de6dd.

PMID:
22274544
20.

Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.

Rosendahl M, Høgdall CK, Mosgaard BJ.

Int J Gynecol Cancer. 2016 May;26(4):680-7. doi: 10.1097/IGC.0000000000000675.

PMID:
26937751

Supplemental Content

Support Center